Logo of Little Green Pharma (ASX:LGP)Latest Little Green Pharma (ASX:LGP) News

Page 2
Page 2 of 4

Little Green Pharma Reschedules Court Date for Cannatrek Acquisition to May 25

Little Green Pharma has pushed back the Federal Court hearing for its Cannatrek acquisition to late May, setting a new timetable that includes a shareholder vote on May 22 and implementation targeted for June 1.
Ada Torres
23 Apr 2026

Little Green Pharma Delays Key Shareholder Vote on Cannatrek Deal to May 22

Little Green Pharma has postponed the shareholder vote on issuing new shares tied to its Cannatrek acquisition, pushing the decision back a month to allow time to meet outstanding conditions. Other resolutions will proceed as planned on April 22.
Ada Torres
21 Apr 2026

Market Wrap - Week 15 (6 Apr -> 10 Apr) 2026

Rare earths, lithium and antimony stocks drove the week, while a handful of capital raisings and profit warnings hit hard. The biggest gains came from drilling wins and deal news. The sharpest falls came where investors faced dilution, weaker earnings or takeover friction.
Logan Eniac
11 Apr 2026

Healthcare Wrap - Week 15 (6 Apr -> 10 Apr) 2026

Small-cap healthcare names produced the biggest share-price swings this week, while larger names advanced on sales growth, trial progress and fresh contracts. Investors rewarded companies that showed clear commercial traction, but fundraising and weak follow-through punished others.
Logan Eniac
11 Apr 2026

Cannatrek Shareholders Approve Scheme for Acquisition by Little Green Pharma

Little Green Pharma Ltd (ASX:LGP) has secured overwhelming shareholder approval from Cannatrek Ltd for its proposed acquisition scheme, advancing the transaction toward Federal Court approval and implementation by early May 2026.
Ada Torres
10 Apr 2026

Healthcare Wrap - Week 14 (30 Mar -> 3 Apr) 2026

Big moves came from point-of-care testing and a sharp sell-off in two names despite upbeat news. Meanwhile, several smaller caps pushed trials and regulatory files forward, giving investors clear dates to watch.
Logan Eniac
4 Apr 2026

Little Green Pharma Updates Cannatrek Acquisition with Revised Timetable and Facility Sale Termination

Little Green Pharma has issued a supplementary scheme booklet updating Cannatrek shareholders on the acquisition progress, including a revised timetable and the termination of a planned sale and leaseback of its WA production facility. Both companies’ boards continue to recommend the scheme, supported by an independent expert’s positive assessment.
Ada Torres
1 Apr 2026

Healthcare Wrap - Week 12 (16 Mar -> 20 Mar) 2026

A handful of small caps did the heavy lifting this week, led by a lung cancer trial green light and a steep sell-off after a capital raise. Investors paid up for clear clinical steps, but punished dilution and stocks that reopened lower and kept sliding.
Logan Eniac
21 Mar 2026

Why Little Green Pharma Walked Away from WA Sale and Leaseback Deal

Little Green Pharma has terminated its planned sale and leaseback of its Western Australian production facility after failing to reach commercial terms, choosing to retain ownership without impacting operations.
Ada Torres
19 Mar 2026

Market Wrap - Week 10 (2 Mar -> 6 Mar) 2026

One stock nearly doubled, another jumped more than 40%, and a finance heavyweight stayed elevated after a merger shock. In resources, the winners were mostly tied to “what was bought” or “what was funded”, while the laggards were often the ones where early optimism quickly turned into selling.
Logan Eniac
7 Mar 2026

Healthcare Wrap - Week 10 (2 Mar -> 6 Mar) 2026

Avecho and Chimeric both surged as traders chased near-term trial and funding catalysts, while Island Pharmaceuticals extended gains on a US biodefence partnership. Elsewhere, distribution and reimbursement wins supported smaller medtech names, and a cannabis merger plan kept Little Green Pharma in focus ahead of April’s vote.
Logan Eniac
7 Mar 2026

Little Green Pharma’s AUD 100M Merger with Cannatrek Gains Independent Nod

Little Green Pharma Ltd (ASX: LGP) has proposed a full acquisition of Cannatrek Ltd via a scheme of arrangement, creating a vertically integrated medicinal cannabis group with pro forma FY26 revenues exceeding AUD 100 million. The scheme, supported by an independent expert, offers liquidity and strategic growth opportunities amid regulatory and market risks.
Ada Torres
5 Mar 2026